Abagovomab for ovarian cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics. CA Cancer J Clin 2006;56:106-30
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
   PubMed Web of Science ®Google Scholar
• Cancer incidence and mortality worldwide in 2008. Lyon, France: Globocan 2008. Available from: http://globocan.iarc.fr/ [Last accessed10 January 2011]
   Google Scholar
• Surveillance, Epidemiology and End Results (SEER) program. Bethesda, MD: Naional Cancer institute 2010. Available from: www.seer.cancer.gov [Last accessed 10 January 2011]
   Google Scholar
• Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 2003;21(Suppl 10):168-74
   PubMedGoogle Scholar
• Du Bois A, Quinn M, Thigpen T, 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):viii7-viii12
   PubMedGoogle Scholar
• Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol 2003;21:2451-3
   PubMed Web of Science ®Google Scholar
• Kufe DW, Pollock RE, Weichselbaum RR, NHI Cancer Medicine. 6th edition. BC Decker, Inc., Hamilton (Canada); 2003
   Google Scholar
• Markman M, Liu PY, Wilczynski S, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Clin Oncol 2003;21:2460-5
   Web of Science ®Google Scholar
• Markman M, Liu PY, Moon J, Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 2009;114:195-8
   PubMed Web of Science ®Google Scholar
• Pecorelli S, Favalli G, Gadducci A, Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 2009;27(28):4642-8
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study [abstract]. 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2010;28(18 Suppl):LBA1
   Google Scholar
• Pfisterer J, Perren T, Swart AM, ICON7: a randomised controlled trial of Bevacizumab in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube [abstract]. International Gynecologic Cancer 6Society (IGCS) 12th Biennnial Meeting; 2010. p. 805. Available from: http://www.igcs.org/Abstract/meeting_2010_805.html [Last accessed 10 January 2011]
   Google Scholar
• Bast RC Jr, Xu FJ, Yu YH, CA 125: the past and the future. Int J Biol Markers 1998;13:179-87
   PubMed Web of Science ®Google Scholar
• Fayers PM, Rustin G, Wood R, The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the medical research council working party on gynaecological cancer. Int J Gynecol Cancer 1993;3:285-92
   PubMed Web of Science ®Google Scholar
• Berek J, Taylor P, McGuire W, Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;27:418-25
   PubMed Web of Science ®Google Scholar
• Braly P, Nicodemus CF, Chu C, The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009;32:54-65
   PubMed Web of Science ®Google Scholar
• Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974;125C:373-89
   PubMedGoogle Scholar
• Schlebusch H, Wagner U, Grunn U, Schultes B. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma 1995;14:167-74
   PubMed Web of Science ®Google Scholar
• Wagner U, Kohler S, Reinartz S, Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001;7:1154-62
   PubMed Web of Science ®Google Scholar
• Reinartz S, Kohler S, Schlebusch H, Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin Cancer Res 2004;10:1580-7
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Dupont J, Aghajanian C, Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006;12:5503-10
   PubMed Web of Science ®Google Scholar
• Pfisterer J, du Bois A, Sehouli J, The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006;17:1568-77
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Berek JS, Casado A, Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial [abstract]. J Clin Oncol 2010;28(Suppl 5036):15s
   PubMedGoogle Scholar
• Du Bois A, Reuss A, Pujade-Lauraine E, Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-44
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Liu PY, Wilczynski S, Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a southwest oncology group trial. Gynecol Oncol 2001;82:317-22
   PubMed Web of Science ®Google Scholar
• Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. Ann Oncol 1997;8:327-33
   PubMed Web of Science ®Google Scholar
• Hakes TB, Chalas E, Hoskins WJ, Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992;45:284-9
   PubMed Web of Science ®Google Scholar
• Barakat RR, Sabbatini P, Bhaskaran D, Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002;20:694-8
   PubMed Web of Science ®Google Scholar
• Paclitaxel or Polyglutamate Paclitaxel or observation in treating patients with stage III or stage IV ovarian epithelial or peritoneal cancer or fallopian tube cancer. ClinicalTrials.gov, 2005. Available from: www.clinicaltrials.gov/ct2/show/study/NCT00108745 [Last accessed 10 January 2011]
   Google Scholar
• BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer. ClinicalTrials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01015118 [Last accessed 10 January 2011]
   Google Scholar
• Efficacy and safety of pazopanib monotherapy after first line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer. ClinicalTrials.gov, 2010. Available from: www.clinicaltrials.gov/ct2/show/NCT00866697 [Last accessed 10 January 2011]
   Google Scholar
• Erlotinib or observation in treating patients who have undergone first-line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer. ClinicalTrials.gov, 2005. Available from: www.clinicaltrials.gov/ct2/show/NCT00263822 [Last accessed 10 January 2011]
   Google Scholar
• Paclitaxel and Carboplatin with or without sorafenib in the first-line treatment of patients with ovarian cancer. ClinicalTrials.gov, 2006. Available from: www.clinicaltrials.gov/ct2/show/NCT00390611 [Last accessed 10 January 2011]
   Google Scholar
• Meier W, Rau J, Huober J, Paclitaxel/Carboplatinum +/- Lonafarnib in first–line treatment of ovarian cancer: a randomized Phase II study by the Ago-Ovar study group [abstract]. International Gynecologic Cancer Society (IGCS) 12th Biennnial Meeting; 2010. p. 435. Available from: http://www.igcs.org/meetings/listAbstracts.html?&AuthorName=Meier&MeetingYear=2010 [Last accessed 10 January 2011]
   Google Scholar
• Temsirolimus, Carboplatin, and Paclitaxel as first-line therapy in treating patients with newly diagnosed stage III or stage IV clear cell ovarian cancer. ClinicalTrials.gov, 2010. Available from: www.clinicaltrial.gov/ct2/show/study/NCT01196429 [Last accessed 10 January 2011]
   Google Scholar
• Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC 16. J Biol Chem 2001;276:27371-5
   PubMed Web of Science ®Google Scholar
• Fendrick JL, Konishi I, Geary SM, CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumour Biol 1997;18:278-89
   PubMed Web of Science ®Google Scholar